Overview

Dinaciclib in Treating Patients With Stage III-IV Melanoma

Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Cyclin-Dependent Kinase Inhibitor Proteins